Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitors
申请人:University of Maryland, Baltimore
公开号:US11078171B2
公开(公告)日:2021-08-03
Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.
COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
申请人:Dana-Farber Cancer Institute, Inc.
公开号:US20200338074A1
公开(公告)日:2020-10-29
The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.
NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS
申请人:University of Maryland, Baltimore
公开号:US20200331874A1
公开(公告)日:2020-10-22
Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.